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Background:  Velocardiofacial syndrome (VCFS) is a congenital malformation syndrome with 
an estimated prevalence of 1:4,000 livebirths.  Most cases are caused by a common 3 Mb 
deletion at 22q11.2.  This syndrome exhibits wide inter- and intra-familial variability in 
phenotypic features including physical, developmental, neurological, and neuropsychiatric 
manifestations despite the general uniformity in deletion size.  The purpose of this meta-analysis 
was to seek explanations for the differences in the reported prevalence rates of various findings; 
to more accurately estimate the prevalence of each of the nine traits examined; to provide insight 
into future research; and to improve the ability for genetic counselors and clinicians to provide 
more appropriate services and offer appropriate resources.  Methods:  A PubMed search was 
performed for keywords associated with VCFS.  After an exhaustive search, twenty-nine articles 
were included.  Nine traits of interest were chosen along with five predictor variables.  From the 
articles, prevalence data was abstracted, overall prevalence data was calculated, and unweighted 
and weighted regression analyses were performed.  Results: Ascertainment bias may be 
associated with the prevalence of ADHD; the prevalence of males does not appear to play a role 
in the discrepant data; the number of years ago a study was published is associated with 
prevalence of ADHD, cleft palate, palatal findings and VPI; age range is associated with the 
prevalence of congenital heart defects; having a de novo deletion is significantly associated with 
the prevalence of cleft palate and SMCP; and geographical location is significantly associated 
 iii
with the prevalence of palatal anomalies.  Overall prevalence rates are as follows: ADHD 17.2%, 
CHD 73.5%, cleft palate 11.6%, submucosal cleft palate 17.0%, velopharyngeal insufficiency 
35.1%, any palatal anomaly 54.1%, any psychiatric disorder 34.4%, schizophrenia 12.6%, and 
hypotonia 64.5%.  Conclusions: Due to small sample sizes, it is difficult to draw conclusions on 
the presented data; however, this analysis provides useful insight into future avenues of research 
especially with regards to behavioral and psychiatric illnesses.  Many findings, especially 
psychiatric illnesses, associated with VCFS, pose a significant public health burden thus it would 
be of public health significance to find answers to some of the questions addressed in this study.   
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1. INTRODUCTION 
 
A meta-analysis of reported prevalence data can be a very useful tool to gain insight into the true 
prevalence of features associated with a genetic syndrome when variability in the literature 
exists.  A meta-analysis serves not only to summarize data but also to seek explanations for the 
variability by analyzing the association between predictor variables and various outcomes.  The 
current meta-analysis examines nine features that are commonly associated with 
Velocardiofacial syndrome (VCFS), a genetic syndrome that has numerous physical 
malformations and behavioral problems associated with it.  Because of the wide variation in 
phenotype in conjunction with the wide variation in reported data regarding these phenotypic 
features, it is extremely difficult to provide genetic counseling and prognostic information to 
families.  Furthermore, it is difficult for clinicians to determine who should have genetic testing 
for this syndrome.  Many clinicians offer testing on a regular basis for any child with 
unexplained behavioral problems and/or speech problems.  It would be more cost-effecient to be 
able to narrow down the population of who is most appropriate to be offered testing.  It would 
also be extremely valuable for clinicians and genetic counselors to be able to tell families in the 
future which children are at-risk to develop the psychiatric disorders such as schizophrenia 
which we know can be associated with this syndrome.  However, this information would not be 
useful for families until early intervention and preventive treatment is available to help these 
individuals.  
In the current study, the following specific aims were pursued: 
Specific Aim 1: To more accurately estimate the prevalence of nine traits commonly 
associated with Velocardiofacial syndrome 
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 Specific Aim 2: To seek explanations for the extreme variability in prevalence rates 
reported for these nine traits  
Specific Aim 3:  To provide insight into future research that will be beneficial to 
clinicians, researchers and families dealing with VCFS 
Specific Aim 4:  To improve the ability of genetic counselors to provide a more accurate 
risk assessment and suggest appropriate resources 
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 2. REVIEW OF LITERATURE 
 
2.1. CLINICAL SPECTRUM OF VELOCARDIOFACIAL SYNDROME 
Velocardiofacial syndrome or 22q11.2 deletion syndrome (MIM# 192430) is a relatively 
common congenital malformation syndrome with an estimated prevalence of 1:4,000 livebirths 
as shown in a large study of 325,000 Belgian children (Devriendt et al., 1998).  This syndrome 
was first described by Shprintzen et al. (1978) as a congenital syndrome presenting with 
hypernasal speech associated with cleft palate or submucosal cleft, conotruncal cardiac defects, 
distinctive facies, learning disabilities, variable IQ, and disturbances in behavior; today, over 180 
clinical features have been associated with VCFS.  Other phenotypic syndromes commonly 
associated with the 22q11.2 deletion include DiGeorge (MIM# 188400) and CATCH22 (Cardiac 
anomalies, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia, and deletion of 
chromosome 22).  Phenotypic features more often associated with DiGeorge syndrome include 
parathyroid hypoplasia, thymic hypoplasia, T cell deficits, and cardiac outflow tract defects.  
CATCH22 primarily acts as an acronym that encompasses all of the features associated with a 
deletion at 22q11.2.  These syndromes were originally thought to be distinct disorders but are 
now thought to be part of a spectrum of clinical manifestations caused by a deletion at 22q.   
 
The characteristic facial findings in individuals with Velocardiofacial syndrome (VCFS) include 
narrow palpebral fissures, tubular nose often with hypoplastic nasal alae, broad nasal bridge, 
small “carp-shaped” mouth, malformed ears and a long face (see Figures 1 and 2).  Other 
problems that have been noted include hypotonia in infancy, conductive hearing loss associated 
with cleft palate, poor fine motor skills, abundant scalp hair, slender hands and digits, small 
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 stature and spinal anomalies such as scoliosis.  Cardiac anomalies and cleft palate are commonly 
reported findings although the actual prevalence is difficult to determine due to many small 
studies, overlapping samples, and ascertainment bias.  The concordance of clefting and heart 
anomalies is not common in the general population.  Shprintzen et al. (1981) reported that of 275 
patients at the Center for Craniofacial Disorders (CCFD) at Montefiore Hospital and Medical 
Center in Bronx, New York, only seven (2.5%) also had a congenital heart anomaly.  This 
suggests that the concordance of clefting and heart anomalies should raise the suspicion of a 
VCFS diagnosis.  
 
 
 
Figure 1 Phenotypic features of  VCFS 
Picture taken from Ryan et al. (1997); shows a phenotypic variability within families.  Bottom left, child with long, 
myopathic face, small mouth, low set ears.  Top right, mother with thick, fleshy nose with bulbous tip, small mouth, 
wide set eyes.  Top left, shows mother and son with mild features of VCFS.   
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Figure 2 Children with VCFS 
Picture from Vantrappen et al (1998); left: child with VCFS with long myopathic face, thick, tubular nose, wide set 
eyes and small mouth; right: child with VCFS with retruded mandible, low set ears, small mouth.   
 
 
VCFS exhibits wide inter- and intra-familial variability in phenotypic features including 
physical, developmental, neurological, and neuropsychiatric manifestations despite the general 
uniformity in deletion size (see Figure 3).  The variability in phenotype is so wide that many 
affected individuals are not identified until having an affected child with a more severe 
phenotype.  It is likely that current prevalence data are underestimates due to mild cases that may 
never present to the medical community.   
 
 
 
 
 
 
 
 
 
5 
  
 
Figure 3 Phenotypic variability within families with VCFS 
Photo from McDonald-McGinn et al. (2001); shows father on right with his two children, all affected.  Child on left 
has autism, small stature, long myopathic face, epicanthal folds, prominent nasal root, bulbous nasal tip; middle 
picture shows child with learning disabilities and auricular abnormalities; father on right has no history of medical or 
educational difficulties, minor dysmorphic features.   
 
 
 
2.1.1.  TWIN STUDIES 
Twin studies can be used to identify genetic and environmental contributions to the variation 
seen in a particular disorder.  Monozygotic (MZ) twins in particular can provide information and 
raise interesting questions regarding genotype-phenotype correlations. Several studies have 
reported MZ twin pairs with 22q11 deletions that are discordant in phenotype.  Discordance in 
MZ twins shows that phenotypic variability cannot be explained by differences in genotype 
alone.  Goodship et al. (1995), described MZ twin males concordant for a 22q11 deletion sharing 
typical facial dysmorphism and nasal speech, yet only one twin had a heart defect, tetralogy of 
Fallot.   In this case, the twins were born to clinically normal, unrelated parents who had no 
family history of congenital heart defects or disease.  The twins were said to have a single 
placenta and the probability of dizygosity of only 0.000156.  Zygosity was determined by 
Southern blot analysis and probing for four hypervariable DNA polymorphisms as well as red 
cell antigens.  High resolution cytogenetic analysis showed 46, XY, del(22)(q11.21q11.23) in 
each twin which was confirmed by FISH analysis.  One hundred metaphases were counted in 
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 each twin and all one hundred showed the deletion.  This, in addition to the dysmorphic facial 
features being so similar, makes it unlikely that mosaicism is an explanation for the discordance.  
It is important to consider however that heart malformations in general are more common in MZ 
twins and when present usually only affect one twin in the pair; the incidence of tetralogy of 
Fallot though is much higher in children with del22q11 than MZ twins (Goodship et al., 1995).  
This study concluded that this twin pair was predisposed to a heart defect due to the 
chromosomal abnormality and that other factors perhaps relating to the twinning process itself 
must have invoked the heart defect in one twin and not the other.  
Singh et al. (2002) describe four additional MZ twin pairs with apparent discordance.  The first 
pair, MZ females, again shared the typical facial features of VCFS but twin 2 had an aortic 
defect requiring surgery during childhood.  The next pair, MZ males born to clinically normal 
parents, had abnormal facies but very little else in common.  Twin 1 had a cardiac defect, thymic 
hypoplasia, velopharyngeal insufficiency, metal retardation (MR) and short stature while the 
other twin had no such complications.  In the next pair, twin 1 had a normal cardiovascular 
system with other abnormalities while twin 2 had similar abnormalities in addition to a cardiac 
defect from which she died at day 5 of life.  The final pair of MZ twins in this report was female 
in which both twins had tetralogy of Fallot with pulmonary atresia.  Twin 1 had facial 
dysmorphism, abnormal outflow septation and misalignment of the great vessels.  This twin died 
at age 11 months of sepsis.  Twin 2 had in addition to tetralogy of Fallot, facial dysmorphism and 
low-normal thymic function.  These studies in conjunction with the fact that over 85% of patients 
with VCFS have a comparable 3Mb deletion raise interesting questions regarding the variable 
nature of the phenotype as well as the susceptibility of this region to become deleted.   
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 2.2. INHERITANCE OF THE 22q11 DELETION 
The recurrence risk for VCFS is low in cases of de novo deletions though there is a small risk of 
germline mosaicism.  In cases of inherited or familial deletions, an individual with the deletion 
has a 50% (1:2) chance of passing it on to each of their offspring apparently due to autosomal 
dominant inheritance.   Genetic counseling in regards to this risk remains difficult due to the 
variability in phenotype.  It has been shown in several studies that parents often have a milder 
phenotype than their affected offspring.  This can be at least partially attributed to ascertainment 
bias since adults with VCFS who go on to reproduce would be more likely to have a milder 
phenotype (e.g. no major cardiac malformation).   
 
The frequency of inherited VCFS deletions varies and has been reported to be between 6% and 
28%; therefore the vast majority of cases occur sporadically (McDonald-McGinn et al, 2001; 
Ryan et al, 1997).  A study by McDonald-McGinn et al. (2001), which ascertained 30 familial 
cases of VCFS through a population of three hundred and seventy affected individuals, suggests 
that the true incidence of inherited deletions is most likely around 10%.  A preponderance of 
maternal transmission is reported in the majority of studies of inherited cases (Driscoll et al., 
1992, Kelly et al., 1993).  For example, Digilio et al. (2003) reviewed the prevalence of parental 
transmission as well as the clinical phenotype of the affected parent.  In a series of eighty-seven 
patients, an affected parent was identified in fifteen (15 or 17.2%) and of these, ten were 
mothers, five were fathers; all were shown to have the typically deleted 3 Mb deletion.  After 
careful examination of the parents with the deletion, one or more clinical feature was identified 
in all except one mother who displayed a very mild clinical phenotype.  Although this was a 
small number of familial cases, this preferential maternal transmission has been demonstrated in 
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 other studies as well such as Swillen et al. (1998) and Ryan et al. (1996).  In the latter study, 
eighty-one patients had an inherited deletion, sixty-one were maternal in origin and eighteen 
were paternal in origin.  With regards to cases of de novo deletions in the same study, initial 
estimates showed a paternal excess, however when the data was combined with previous reports 
by Demczuk et al. (1995), no parent of origin preference was noted.  Hypothesized explanations 
for an excess of maternally inherited deletions include decreased fertility in male carriers, 
ascertainment bias, and imprinting.  Imprinting can most likely be ruled out since most 
individuals with reported maternal uniparental disomy 22 have a normal phenotype (Balmer et 
al., 1999).  Paternal uniparental disomy however, has not been reported to date.   
 
In contrast to studies supporting a maternal excess of inherited deletions, there does not appear to 
be a parent-of-origin preference in de novo cases.  Saitta et al. (2004) examined sixty-five cases 
of de novo deletions and used multiple microsatellite markers to determine the parent of origin; 
thirty-five cases were maternal in origin and thirty were paternal in origin.  A smaller study by 
Ravnan et al. (1996) identified thirty-one deletions in a group of one hundred individuals with 
suspicious features of VCFS.  Of these thirty-one cases, four were familial and three of these 
four were maternally inherited.  There appears to be no difference in phenotype when the 
deletion is familial in nature versus when it occurs de novo.   
 
2.3. CYTOGENETIC ANALYSIS OF 22q11 DELETION 
Due to advances in cytogenetic technology and the use of fluorescent in situ hybridization 
(FISH), detection of VCFS is more accurate and the results are easier to interpret as compared to 
traditional high-resolution Giemsa banding.  It is well established that the cytogenetic 
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 abnormality in VCFS is a microdeletion at chromosomal location 22q11.2; most cases (87%) 
involve a 3 Mb region of the genome.  Approximately 7-8% have a smaller 1.5 Mb deletion that 
lies within the 3 Mb region; thus this 1.5 Mb region is involved in over 95% of cases.  An 
additional 4% have one of two other nested deletions and the remainder have unique deletions 
(Shaikh 2000, Ivanov 2003, Saitta, 2004) (Fig .1).  Despite the vast majority of cases having a 
common 1.5 Mb deletion, there is great variability in the disorder as discussed earlier.   
 
 
 
Figure 4: Chromosome 22: common deletions associated with VCFS 
Shows the distribution of the genotyped markers in the typically deleted region of Velocardiofacial syndrome as 
well as the low copy repeats on chromosome 22q11.2.  Ivanov, D. et al., 2002 
 
 
 
The region that is typically deleted in VCFS is associated with other syndromes and recurrent 
rearrangements as well, including duplication 22q, Cat-Eye syndrome, a translocation (t11;22) 
that gives rise to derivative (22) syndrome, and other translocations and deletions that are 
associated with DiGeorge syndrome and Conotruncal Face Anomaly syndrome (CFAS).   
10 
 Recurrent constitutional rearrangements such as these suggest that genomic instability exists in 
this region or that this is a site of preferential recombination that leads to a greater frequency of 
rearrangements.  The high prevalence of VCFS in addition to the fact that most cases are 
sporadic in nature provide evidence that there is likely a common molecular basis for 
rearrangements at 22q11. Many studies concur that four large (200-500 kilobases), highly 
homologous low copy repeats (LCR’s A, B, C, D) presumably confer instability and therefore 
lead to aberrant recombination in this region (Saitta, 2004; Edelmann et al., 1999; Shaikh., 2000; 
Shaikh., 2001).  These low copy repeats are found within and flanking the 3Mb typically deleted 
region associated with VCFS (Fig 1).  Additional LCR’s exist on chromosome 22 but do not 
appear to have significant involvement in recurrent rearrangements.   
 
There had been much discussion in past literature with regards to whether deletion 22q syndrome 
is a contiguous gene deletion syndrome or whether there exists a single gene responsible for the 
phenotype.  The absence of an obvious genotype-phenotype correlation in conjunction with 
numerous reports of patients with the classic VCFS/DiGeorge phenotype and an atypical deletion 
excludes this disorder from being a contiguous gene deletion syndrome.  In terms of the single 
gene theory, several genes have been proposed as candidate genes responsible for the phenotype 
while the other deleted genes in the region may act as modifiers of the phenotype thereby 
explaining the variability.  It has been hypothesized that VCFS is a developmental field defect 
and the phenotypic differences observed reflect the events that affect the differentiation of 
structures during neural crest cell migration.  Neural crest cells are critical in the development of 
the jaw, thymus, outflow tract of the heart (conotruncal region) and disruption of the migration 
of these cells can cause abnormalities in these structures as well as facial dysmorphism, all 
11 
 structures which have been reported to be associated with having a deletion of 22q.  Several 
genes within the deleted region have been shown to be involved in neural crest cell migration.  
One gene in particular is the UFD1L gene (DeDecker et al., 2001).  UFD1L was shown to be 
deleted in all one hundred-eighty two patients in a study performed by Yamagishi et al. (1999).  
Furthermore expression of this gene was shown in various structures that are frequently affected 
in individuals with the deletion such as the conotruncal region, palatal precursors, and the 
hippocampus which may have a role in learning disabilities.  Other genes thought to be critical in 
neural crest cell migration include the TUPLE1 gene, a transcription factor expressed at critical 
point in development of the outflow tract of the heart, and TBX1 another transcription factor 
expressed in early embryogenesis of the pharyngeal pouches.   
 
2.4.   SCHIZOPHRENIA IN VCFS 
Schizophrenia is a severe and disabling mental illness with unknown etiology characterized by 
delusions, hallucinations and disorganized speech and behavior.  It has an estimated prevalence 
of 1% in the general population and 25-30% in individuals with VCFS (Murphy et al, 1999; 
Pulver et al, 1994; and Bassett et al, 2000).  Schizophrenia like many other psychiatric disorders 
appears to have both genetic and non-genetic factors influencing its development.  Research 
shows that children with one parent meeting criteria for schizophrenia are 10-15 times more 
likely to develop schizophrenia as adults; those with two affected parents are 40 times more 
likely to develop schizophrenia when compared to children with normal parents (Cornblatt and 
Erlenmeyer-Kimling, 1985).  Moreover, twin studies have shown that the genetically identical 
twin of an individual with schizophrenia has a 40-50% chance of also developing schizophrenia.  
Determining specific genetic and environmental factors would greatly increase the ability to 
12 
 develop appropriate treatments and/or preventive measures and initiate early intervention 
strategies.   
 
Numerous independent loci have been linked to schizophrenia; some such as the linkage on 
22q11.2 seem to be robust in that a large proportion of deleted individuals develop schizophrenia 
(Murphy et al. 1999, Shprintzen, 1992, and Pulver, 1994).  A study conducted by Murphy et al. 
(1999) evaluated 50 adults with VCFS in an attempt to characterize the psychiatric phenotype.  
Once categorized, individuals with schizophrenia and VCFS (SZ/VCFS, n=12) were compared 
to a control group of individuals with schizophrenia but without a deletion on chromosome 22q 
(SZ).  This study revealed that 42% (21 individuals) had a history of a major psychiatric 
disorder, and 30% (15 individuals) had a history of psychosis. Twenty-four percent (24% or 12 
individuals) met DSM-IV criteria for schizophrenia.  Six individuals with VCFS and psychosis 
were referred by psychiatric services thus presenting an ascertainment bias, but excluding these 
six subjects, the rate of psychosis remains much higher (18%) than would be expected.   It was 
suggested that the high prevalence of schizophrenia in particular in this study might reflect a 
non-specific association with mental retardation since 33% of those with VCFS had mental 
retardation (predominantly mild).  However, the rate of schizophrenia in the mentally retarded 
population outside of VCFS is estimated to be around 3% (Murphy et al, 1999), higher than that 
of the general population yet still much lower than the observed 24% in this study.  Therefore, 
this explanation does not likely account for the increased prevalence rate observed.   
Additionally, this study found a significantly later age of onset of schizophrenia in the SZ/VCFS 
group when compared to the SZ group.  Mean age of onset in the SZ/VCFS group was 26 years 
whereas in the SZ group it was 19 years.  Conflicting data regarding age of onset of 
13 
 schizophrenia in individuals with VCFS exists as other studies demonstrate an association with 
early-onset schizophrenia.  The incidence of 22q11 deletion was examined in a series of patients 
with childhood-onset schizophrenia (COS).  Usiskin et al. (1999) screened forty-seven patients 
with COS and found that three (6.4%) had a deletion of chromosome 22q11.  All three 
individuals were said to have premorbid impairments of language, motor and social 
development.  These results provide evidence that these deletions are in fact associated with 
schizophrenia and may be associated with an earlier age of onset.   
 
There is also conflicting reports of the rates of schizophrenia in those with VCFS.  In a study by 
Papolos et al. (1996; n=25), 64% met DSM-III-R criteria for a spectrum of bipolar affective 
disorders but there were no individuals meeting similar criteria for schizophrenia.  Some studies 
have examined the rate of the 22q deletion in populations of patients with schizophrenia in an 
attempt to better characterize the incidence.  One study by Lindsay et al. (1995) identified the 
deletion in two out of one hundred (2/100) individuals with schizophrenia, these individuals were 
not prospectively evaluated for features of VCFS.  A second study (Sugama et al., 1999) 
screened three hundred twenty six patients admitted to a Japanese psychiatric hospital for 
features suggestive of VCFS, twelve were identified.  Of these twelve patients, six were 
underwent further evaluation by FISH and one was found to have the deletion on chromosome 
22.  Another study by Bassett et al. (1998) assessed seventeen subjects with schizophrenia or 
schizoaffective disorder with two or more features suggestive of VCFS.  Of these seventeen 
subjects, ten were found to have a deletion by FISH.  Discrepancies in the published data are 
likely due to small sample sizes and differences in the modes of ascertainment.  Most of these 
studies support a link between schizophrenia and a deletion on chromosome 22q11.2.   
14 
 2.4.1. IMPAIRED ATTENTION AND SCHIZOPHRENIA 
Schizophrenia is characterized by psychosis, negative symptoms such as flat affect or decreased 
pleasure, and cognitive impairment especially in terms of attentional deficits.  Cognitive domains 
that have been studied most extensively in schizophrenia are attention, memory and executive 
function.  Impaired sustained attention is a strong premorbid indicator of risk for schizophrenia 
as noted in numerous studies (Cornblatt and Keilp, 1994; Liu, et al, 2002).  A study by Liu et al, 
2002, suggested that impairment in sustained attention may differentiate schizophrenia from 
other psychotic disorders.  When schizophrenics were compared to bipolar patients with and 
without psychosis and individuals with major depression without psychosis, those with 
schizophrenia had the highest level of impairment followed those with bipolar disorder.  The 
Continuous Performance Test, which measures sustained attention, showed that the deficits 
observed in patients with bipolar disorder improved from the time of inpatient admission to 
discharge whereas those in schizophrenics remained unchanged.  They concluded that the 
deficits measured by the CPT are stable indicators of the vulnerability to schizophrenia.  Other 
studies concur that there is no significant difference in the performance of acute schizophrenics 
versus those in remission.  Additional studies involving the CPT test have also shown that it was 
possible to distinguish normal controls from patients with schizophrenia who are in remission 
(are not acute).  Others have shown that attention performance is worse in first-degree relatives 
with schizophrenia than those who have no family history (Suwa et al., 2004; D’Amato et al., 
1998).  Thus it has been proposed that poor performance on attentional tasks may suggest a 
vulnerability to the development of schizophrenia.   
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 2.4.2. ABNORMALITIES IN DOPAMINE NEUROTRANSMISSION 
It has long been postulated that disturbances in dopamine neurotransmission may play an active 
role in the development of schizophrenia.  Dopamine has many roles within the brain; in the 
prefrontal cortical region in particular, it is linked to functions such as memory, attention and 
problem solving.  Deficits involving these cognitive domains are cardinal features of 
schizophrenia as discussed earlier.  The mesolimibic pathway of the brain is thought to 
contribute to the positive symptoms (hallucinations, delusions) seen in schizophrenia while the 
mesocortical pathway is thought to be associated with the negative symptoms (flat affect, lack of 
desire or emotion) of schizophrenia.  The mesolimibic and mesocortical pathways are two of the 
four major pathways where dopamine is found.  Evidence for the dopamine hypothesis of 
schizophrenia or psychosis came from the effects of drugs such as cocaine or other 
amphetamines which greatly increase the levels of dopamine causing psychotic-like symptoms.  
In addition, the discovery of a group of drugs called phenothiazines which include commonly 
used anti-psychotic drugs, block the uptake of dopamine at receptors and reduce psychotic 
symptoms.  Although dopamine is not likely to be the only neurotransmitter involved in 
psychosis, there is much evidence to support its importance.  Interestingly, COMT is a gene in 
the 22q deleted region which has been implicated in the pathogenesis of schizophrenia due to its 
effect on dopamine catabolism and further evidenced by the frequency of schizophrenia in those 
with a deletion in this region.   
 
Catechol-O-methyltransferase (COMT) is an enzyme involved in the breakdown of the 
catecholamine neurotransmitters including dopamine, epinephrine and norepinephrine.  COMT 
is responsible for more than 60% of the degradation of dopamine in the frontal cortex region of 
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 the brain (Malhotra et al., 2002).  The gene that encodes this enzyme, also known as COMT, has 
been investigated as a candidate gene for schizophrenia.  The functional polymorphism, G → A, 
at codon 158 results in a substitution of methionine (Met) for valine (Val) and has been identified 
in association with schizophrenia.  This substitution alters the activity of the COMT gene with 
the Val allele resulting in high activity and the Met allele resulting in low activity.  
Homozygosity for the Met allele leads to a 3-4 fold reduction in enzyme activity when compared 
to homozygosity of the Val allele (Ohmori et al., 1998, Egan et al., 2001).  Heterozygotes for the 
two alleles (Val/Met) have activity levels midway between the homozygote levels.  Thus 
homozygotes for the Val allele have increased dopamine catabolism and are hypothesized to be 
associated with deficits involved in the functions of the prefrontal region of the brain, where 
dopamine plays an active role.  In studies on laboratory animals, low levels of dopamine have 
demonstrated cognitive impairments whereas in human studies, the enhancement of 
dopaminergic activity has improved cognitive functioning.  These provided evidence for the role 
of the COMT gene in schizophrenia.  
 
Conflicting data has been published in the literature regarding the effects of the Val and Met 
alleles on cognition and also their prevalence in the schizophrenic population.  Some studies 
have shown an association of the high activity Val allele and schizophrenia (Wonodi et al, 2003; 
Egan et al, 2001) or similarly, that individuals with the Met allele performed better on tests of 
prefrontal cognitive functions (Malhotra et al., 2002 and Bilder et al., 2002).  Nevertheless, other 
studies have found no association between the Val and Met alleles and performance on tasks 
involving similar cognitive functions.  A study by Shifman et al. (2002) did not reveal an 
association with the Val/Met alleles and schizophrenia but did however demonstrate a highly 
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 significant association between the COMT gene and schizophrenia by haplotype analysis.  It is 
possible that some of this conflict may be explained by ascertainment bias or by differences in 
testing techniques.   
 
2.5. ATTENTION DEFICT/HYPERACTIVITY DISORDER AND VCFS 
It has been well established that hemizygosity for the 22q11 region is associated with several 
behavioral and psychiatric illnesses in both childhood and adulthood.  The behavioral phenotype 
in VCFS has been characterized more specifically by developmental delays, cognitive and 
language deficits as well as the presence of psychiatric disorders, and childhood abnormalities of 
attention, mood and anxiety.  Children with VCFS often display bland affect, social difficulties, 
and extremes of behavior, from shy and withdrawn to disinhibited and impulsive (Murphy, 2004; 
Gerdes et al., 1999).  Studies of cognition and behavior profiles of children with a deletion of 
22q reveal a range in IQ levels from normal to moderate mental retardation.  Verbal IQ is often 
significantly higher than performance IQ regardless of IQ status (Moss et al., 1999; Swillen et 
al., 1997).  They report that although many children with VCFS have delayed language skills, 
which often represent later problems in reading and spelling, verbal IQ scores are consistently 
higher than performance.  Attention deficit-hyperactivity disorder (ADHD) has also been 
associated with 22q deletion syndrome and has been hypothesized to play a role in the 
aforementioned neurocognitive profile (verbal IQ > performance IQ).  The IQ profile in children 
with ADHD without VCFS is often the opposite in that they typically have higher performance 
IQ’s than verbal (Moss et al., 1999).   
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 Attention deficit-hyperactivity disorder typically becomes apparent in the preschool or early 
school-age years.  ADHD is not easy to diagnose as all children may exhibit some of the 
symptoms at a low level.  Typical symptoms or behaviors are inattention, hyperactivity and 
impulsivity.  Symptoms may appear at different times and may be more or less pronounced in 
certain settings such as school, home or social relationships.  According to the Diagnostic and 
Statistical Manual for Mental Disorders (DSM-IV), there are three subtypes of ADHD: 
predominantly hyperactive-impulsive, predominantly inattentive, or combined type.  Diagnostic 
guidelines state that behaviors consistent with ADHD must be demonstrated to be inappropriate 
for the person’s age, appear before age seven years, continue for at least six months and create a 
handicap in two areas of the person’s life including social situations, home-life, or the classroom 
setting.   
 
Several studies have evaluated children with VCFS to determine the rate of ADHD in this 
population.  Papolos et al., (1996) performed psychiatric evaluations on twenty-five individuals 
over the age of five years with VCFS and found that five of them (20%) met DSM-III-R criteria 
for ADHD and four others (16%) met criteria for Attention Deficit Disorder without 
hyperactivity (formerly known as ADD but now considered to be part of the ADHD spectrum).  
A more recent study by Gothelf et al., (2004) evaluated fifty-one patients with VCFS, ADHD 
was diagnosed in twenty-one individuals (41.2%).  Furthermore, this study examined the first 
degree relatives of patients with ADHD and found a significantly higher incidence of ADHD in 
these family members as compared to the first degree relatives of the patients without ADHD 
(OR = 5.9, p=0.006).  In this study there was no significant difference in IQ of the two groups of 
patients (those with and without ADHD).  The rate of ADHD in the general population is 
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 estimated to be 3-7% of children, much lower than that shown by Papolos et al and Gothelf et al.  
The increased frequency of ADHD in children with VCFS suggests that the deleted region of 
genes on chromosome 22q may contribute to the etiology of ADHD.  Interestingly, another 
group demonstrated that the COMT gene, which is also located in the typically deleted region, 
was associated with ADHD in a non-VCFS population of males (Gothelf et al., 2004). 
 
2.6. CARDIAC ANOMALIES AND VCFS 
Congenital heart defects (CHD) may occur as either an isolated defect or as part of a genetic 
syndrome.  Certain types of cardiac defects are often over-represented in syndromes when 
compared with the general population.  Typical cardiac defects associated with deletion 22q 
syndrome are conotruncal, meaning that they derive from the embryonic aortic arches and the 
ventricular septum.  Malalignment and incomplete septation of these structures gives rise to the 
most commonly observed defects in VCFS: ventricular septal defects (VSD), tetralogy of Fallot 
(TOF), and right aortic arch (RAA).  Truncus arteriosus, interrupted aortic arch and TOF are the 
most common congenital heart defects observed in DiGeorge syndrome; thus because the 
deletions in DGS and VCFS are indistinguishable, any one of these defects may be important in 
the diagnosis.  Abnormalities of the cardiac valves or myocardium are rarely seen in deletion 22 
syndrome.  Moreover, it has been observed that patients with a CHD may be diagnosed as non-
syndromic in infancy but are later found to have a deletion.  This is because some features 
associated with the deletion are not detectable until later in childhood such as delayed speech, 
hypernasal speech or VPI, and subtle facial dysmorphism.  The frequency of identifying a 
deletion in these individuals is dependent upon the particular cardiac defect that is present.   
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 Studies have been done on populations of individuals with presumably isolated cardiac defects to 
determine the frequency of deletions.  It has been suggested that a 22q deletion may account for 
up to 15% of individuals with an isolated conotruncal cardiac defect (Cuneo, 2001; DeDecker, 
2001).  An early study which examined seventeen individuals with a conotruncal defect not 
previously diagnosed with a deletion, showed that five patients (5/17) had a deletion at 22q 
(Goldmuntz, 1993).  In 1997, Goldmuntz et al demonstrated that in a population of 50 seemingly 
non-syndromic individuals with cardiac defects (TA, IAA or TOF), nine had a deletion.  Both of 
these studies have small sample sizes however, a subsequent study also by Goldmuntz et al 
(1998), ascertained a group of two hundred fifty-one patients diagnosed with one of seven 
different conotruncal defects; these individuals were then screened for a 22q11 deletion.  Of 
these two hundred fifty-one patients, forty-five patients (17.9%) had a detectable deletion by 
FISH.  The deletion was most frequently associated with IAA (50% or 12/24), TA (34.5% or 
10/29), TOF (15.9% or 20/126), and posterior malalignment type ventricular septal defect 
without interruption of the aortic arch (PMVSD) (33.3% or 2/6).  These findings demonstrate 
that IAA, TA and TOF may be important clues to the early diagnosis of deletion 22q syndrome.   
 
2.7. PALATAL DEFECTS AND VCFS 
2.7.1. CLEFT PALATE 
Non-syndromic inheritance of facial clefting (cleft lip, cleft palate or cleft lip and palate) is 
multifactorial in nature and occurs with varying frequency depending upon family history.   For 
isolated cleft palate in particular, the risk to future offspring is up to 7% with one affected parent, 
2-5% when one sibling is affected, and up to 20% when one sibling and one parent are affected.   
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 In general, isolated clefts of the palate are twice as common in females as in males and the rate is 
constant among different ethnic groups.  Isolated cleft palate accounts for about 30% of facial 
clefts.   
 
Certain chromosome abnormalities are associated with an increased occurrence of clefting; facial 
clefts are associated with a genetic syndrome 15-60% of the time.  Common syndromes that may 
include cleft palate are Apert syndrome, Stickler syndrome, Treacher Collins and deletion 22q 
syndrome.   The incidence of cleft palate in the VCFS population has been reported to be as low 
as 8% (Swillen, 1997) and as high as 85-98% (Thomas et al., 1997) depending upon the mode of 
ascertainment; clearly those ascertaining subjects through craniofacial centers will have much 
higher incidences.  The majority of studies however report ranges closer to 13-28% when using 
mixed ascertainment methods.  Nevertheless, there is considerable discrepancy in these reports.   
 
Patients with cleft palate often have additional medical problems relating to their cleft.  
Eustachian tube dysfunction is commonly seen due to abnormal insertion of muscles into the 
hard palate and/or hypoplasia of the Eustachian tube.  This can potentially result in conductive 
hearing loss. Eustachian tube dysfunction typically decreases as the child ages and in many cases 
normalizes by mid-adolescence.   Proper treatment and management is necessary in these 
patients in order to provide adequate hearing and prevent deterioration of the tympanic 
membrane.  Most patients require myringotomy and tube placement several times throughout 
their childhood in addition to cleft palate repair.   
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 In addition to Eustachian tube dysfunction, the presence of a cleft palate alters the way the 
velopharyngeal sphincter muscle works to close off the opening between the nasal passage and 
the mouth which is important during speech and swallowing.  When the muscle incompletely 
closes off this opening it is termed velopharyngeal incompetence or insufficiency.  This leads to 
an audible escape of air from the nose (nasal emission) when the individual attempts to produce 
sounds involving a build up of air pressure.  Nasal emission results in hypernasal speech which 
can render a person’s speech difficult to understand.  Velopharyngeal dysfunction can occur with 
or without the presence of a cleft palate.   
2.7.2. VELOPHARYNGEAL INSUFFICIENCY 
Velocardiofacial syndrome is one of the leading causes of cleft palate and velopharyngeal 
insufficiency (Vantrappen et al., 1998).  Velopharyngeal competence is said to be the most 
important factor in articulation and listener understanding of speech in those with cleft palate.  
Patients with cleft palate often demonstrate errors in articulation usually due to velopharyngeal 
incompetence.  In the English language, very few sounds, when made correctly, should resonate 
nasally (“m”, “n” and “ng”).  Most other consonants are referred to as pressure consonants and 
require velopharyngeal closure.  When air escapes through the nose it can sound like squeaks or 
snorts and may make speech difficult to understand.  This can lead to a decreased quality of life 
due to the perception that individuals with hypernasal speech may be less intelligent or less 
attractive than individuals with normal speech.  These false perceptions can affect the person’s 
self-esteem and social-life.   
 
Speech and language delay is one of the most consistent features associated with VCFS due in 
part to velopharyngeal insufficiency.  In children without major physical findings, evaluation for 
23 
 apparent idiopathic speech and language delay often leads to the diagnosis of deletion 22q 
syndrome.  Although it is true that many children with VCFS have decreased IQ levels, the 
speech and language delay is often associated with underlying VPI and sometimes hearing loss.  
It has been shown that although speech and language are delayed, language comprehension is 
often normal when compared to age related levels (Vantrappen et al., 1998).  Published reviews 
report discrepant prevalence data of velopharyngeal dysfunction leading to confusion as to the 
true prevalence.  Two large studies however report similar rates of VPI of 32% and 27% (Ryan 
et al., 1997 and McDonald-McGinn et al., 1999 respectively).  An overt cleft palate is easily 
recognized at birth but a submucosal cleft of the palate (SMCP) can only be diagnosed with 
careful examination.  Early diagnosis of velopharyngeal insufficiency due to submucosal cleft 
palate can provide support for early intervention and speech therapy.  Speech therapy is an 
important part of treatment for children with VPI but the accompanying learning disabilities and 
behavioral problems can complicate progress and have a limiting role in success.  Earlier 
treatment leads to an improved prognosis.   
2.8. HYPOTONIA AND VCFS 
A history of hypotonia has been reported in velocardiofacial syndrome and may have long-term 
effects on the development of the individual.  Global hypotonia may affect the acquisition of 
gross motor skills as well as velopharyngeal function and Eustachian tube dysfunction due to 
hypoplasia of these structures.  Although hypotonia is a common finding in infants requiring 
surgical intervention for a heart defect, it can be found in children with VCFS without a co-
existing cardiac defect.  Hypotonia is a very non-specific finding in and of itself.   
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 2.9. META-ANALYSIS 
Meta-analysis falls under the research category of systematic review and most are based on 
summary of data published in articles.  Some are based on individual patient data.  While the 
latter format is probably more accurate, it is often not an option or is too time-consuming.  All 
meta-analyses follow four basic steps: 1) choosing data sources 2) creating inclusion/exclusion 
criteria for study selection 3) data abstraction and 4) statistical analysis.  It is important to try to 
choose a good balance for study selection because being too restrictive can limit the ability to 
generalize results while being too inclusive can weaken the confidence that can be placed in the 
findings.   
 
The phenotypic variability observed in velocardiofacial syndrome is great and therefore trying to 
estimate the prevalence of specific traits is confounded by many published papers reporting 
variable rates of manifestations.  Much of the discrepancy may reflect ascertainment bias and 
small sample sizes.  Moreover, many articles publish data on cases which have been previously 
reported.  By combining data from various studies, it is possible to create a larger sample thereby 
increasing statistical power and, if done carefully, this type of study can minimize or eliminate 
sample overlaps.  Meta-analysis allows us to combine studies in order to reach general 
conclusions.   
 
Meta-analysis clearly has some advantages over other methods of study but it is not infallible.  It 
can be subjective in that it integrates results which the reviewer feels are combinable.  Bias may 
be introduced depending upon the inclusion or exclusion criteria used to determine the data that 
will be used.   Literature search bias is common as well as not every study may be published in 
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 every database.  Publication bias can also be a problem in that significant results are more likely 
to be published than non-significant results.  In addition to the introduction of bias, the examiner 
may need to make decisions regarding how to interpret and categorize some data as it is not 
always stated clearly.  There is also the potential for data to be reported more than once although 
efforts are made to avoid this.  Finally, limitations exist to every meta-analysis in terms of 
language of publications (English only in this case) and access to publications.   
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 3.   MATERIALS AND METHODS 
3.1. STUDY SELECTION 
A PubMed database search was performed for articles published in the English language since 
1978 using the following search terms: “velocardiofacial syndrome”, “velocardiofacial syndrome 
and clinical manifestations”, “velocardiofacial syndrome and phenotype”, “velocardiofacial 
syndrome and behavior”, “velocardiofacial syndrome and cardiac”, “VCFS and clinical 
manifestations”, VCFS and phenotype”, “VCFS and cardiac”, “DiGeorge syndrome and clinical 
manifestations”, DiGeorge syndrome and behavior”, “DiGeorge syndrome and phenotype”, 
“DiGeorge syndrome and cardiac”, “deletion 22q syndrome”, “deletion 22q11.2”, “CATCH22 
and clinical manifestations”, and “CATCH22 and phenotype”.  Preliminary searches resulted in a 
maximum of two hundred forty-three articles containing these keywords.  Of these two hundred 
forty-three articles, eighty-seven articles were selected based on relevance to this research in that 
there was data published on traits of interest.   
 
Articles were obtained and systematically reviewed to determine if there was an overlap in 
samples or if they included previously published data.  This was done by recording the 
city/country in which the research was conducted and the method by which the samples were 
obtained.  Additionally, all bibliographies were cross-referenced.  We also reviewed all authors 
listed in an attempt to further define any overlaps.  When sample overlaps were detected or 
suspected based primarily on geographic location of sample ascertainment, generally the article 
with the larger sample size (n) was chosen.  On occasion, articles with overlapping samples were 
used however the specific data was only used once.  For example, two articles by Gothelf et al. 
(2003, 2004) were used, the samples are assumed to be overlapping but one provided palatal data 
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 while the other provided primarily psychiatric data.  Every effort was made to ensure that case 
data was used only once in this analysis.   
3.2. DATA COLLECTION 
Data of interest that was obtained from each study when available included the year the study 
was published, total number of cases (n), ascertainment method, location of the study (city, state, 
country), age range, male to female ratio, type of deletion (de novo or inherited) and prevalence 
data on the following traits: ADHD, CHD, hypotonia, palatal defects, VPI, SMCP and CP, 
schizophrenia, any other psychiatric disorder.  These nine traits were evaluated as the outcome 
variables (dependent variables) and the predictor variables were as follows: ascertainment type 
(see below for coding information), prevalence of males, # of years ago the study was published, 
age range (see below for categories), prevalence of de novo deletions, and the continent on which 
the subjects were ascertained (Europe or North America).   
 
When summarizing the data, it was noted that some authors reported traits differently than 
others.  Some authors delineated between overt clefting of the palate, submucosal cleft palate, 
and VPI, whereas other authors simply reported these findings in sum as palatal anomalies.  
Efforts were made to categorize these as accurately as possible.  Referring to Table 9 in the 
appendix, the “Palatal anomalies” category combines all data categorized as CP, SMCP, and 
VPI.  In some articles, data was given as combinations such as “VPI or CP” and therefore was 
only documented as “palatal anomalies”.  The VPI category includes data reported either as VPI 
or as hypernasal speech since hypernasal speech is generally associated with velopharyngeal 
insufficiency.  When cleft palates were not subcategorized as SCMP or overt CP, they were  
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 documented in total as CP.  The category “psychiatric disorder” includes data from the studies 
regarding any psychiatric diagnosis as stated by the authors of the study and also includes those 
individuals reported to have schizophrenia.   
3.3. EXCLUDED STUDIES 
Articles that were not available through the Health Sciences Library System at the University of 
Pittsburgh were not included in the current study (less than five).  Articles reporting data on 
monosomy 22q due to translocations or other rearrangements were also not included.  
Furthermore, articles that contained only case reports or family reports that examined less than 
five families were excluded as well in an attempt to minimize reporting bias.  In all, twenty-nine 
studies met the inclusion criteria (failed to meet the exclusion criteria) and were selected for this 
study.  Of the fifty-seven remaining articles, nineteen were excluded because they reviewed 
previously published data by other groups, six articles were excluded because they were case or 
family reports, and sixteen were excluded due to suspected or reported sample overlaps.  In 
addition, some articles were excluded due to obvious ascertainment bias.  For example, three 
articles were excluded because the subjects were ascertained for cleft palate and then the 
prevalence of the deletion was determined.  Only palatal data was provided in these studies.  
Similarly, four articles were excluded due to subject ascertainment by heart defect, again only 
cardiac data was presented.  Lastly, ten articles were excluded because they ascertained subjects 
with schizophrenia or psychosis and only the data regarding these diagnoses was provided.   
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 3.4. INCLUDED STUDIES 
Data used for this analysis was extracted from the following twenty-nine published articles: 
Arnold et al., 2001; Botto et al., 2003; Digilio et al., 2003; Driscoll et al., 1992; Du Montcel et 
al., 1996; Eliez et al., 2000; Feinstein et al., 2002; Ford et al., 2000; Gerdes et al., 1999; Gothelf 
et al., 2004; Gothelf et al., 2003; Havkin et al., 2000; Hopkin et al., 2000; Kelly et al., 1993; 
Kerstjens-Frederikse et al., 1999; Kitsiou-Tzeli et al., 2004;  Leana-Cox et al., 1996; McDonald-
McGinn et al., 1999; McDonald-McGinn et al., 2001; Meinecke et al., 1986; Murphy et al., 
1999; Niklasson et al., 2001; Oskarsdottir et al., 2004; Papolos et al., 1996; Ravnan et al., 1996; 
Ryan et al., 1997; Shprintzen et al., 1978; Shprintzen et al., 1981; and Swillen et al., 1997.   
Of note, the Ryan et al., 1997 article states that some subjects were likely previously reported but 
did not specify how many; therefore it was not possible to determine which studies included here 
may overlap with this sample.  The data provided by this study was included in the current study 
due the potential importance of including a sample this size.  
 
3.5. ASCERTAINMENT CODING 
In order to compare trait results based on ascertainment of subjects the different types or 
locations of ascertainment were coded.  Studies in which ascertainment was restricted to 
craniofacial centers were coded as 1 (CC=1), VCFS clinics were coded as 2 (VCFS=2), medical 
or clinical genetics clinics were coded as 3 (GEN=3), mixed ascertainment was coded as 4 
(MIX=4) and those not fitting these categories were coded as 5 (OTHER=5).  Category 5 also 
included studies in which the ascertainment was not clearly specified in the article.  The majority 
of studies were coded as mixed (4) or other (5) (twelve were mixed, eight were other).  Four 
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 studies were coded as 1 (CC), four as 3 (GEN) and one as 2 (VCFS).  In the “other” category, 
four articles did not clearly state their ascertainment modes, one study ascertained subjects 
through behavioral clinics, one study ascertained through a VCFS association in addition to 
using web advertising (therefore we do not know how these subjects were initially ascertained), 
one study that evaluated all children in a certain age group though testing laboratories, and 
finally one study which evaluated the parents of children with VCFS who also were found to 
have the deletion.   
3.6. AGE RANGE CATEGORIES 
Very few studies provided the specific age of each subject in conjunction with their phenotypic 
information for each subject.  Most studies however, did provide a range of ages; in others, it 
was possible to infer the range.  In order to perform analyses on this type of data, age categories 
were created.  Because many of the traits of interest are evident at birth or in early childhood 
with the exception of some behavioral and psychiatric illnesses, the age categories created were 
based on suggested evidence for childhood to early adolescent onset of these findings in the 
VCFS population (Feinstein and Eliez, 2000; Papolos et al., 1996; Gerdes et al., 1999).  Based on 
these articles, the assigned categories are in reference to age fifteen years.  Those studies 
including subjects both younger and older than fifteen years make up the “mixed” (m) category.   
The “older” (o) category means that all subjects are ≥ 15 years of age, and the “younger” (y) 
category includes subjects under the age of fifteen years.  Of the twenty-seven studies that 
reported age ranges, the majority (18/27) fell into the mixed age range category.  Data from 
seven studies fell into the younger (y) category while only two consisted of populations that were 
older than the cutoff age. 
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 3.7. STATISTICAL ANALYSIS METHODS 
In the twenty-nine studies reviewed, there were a total of 1,588 individuals with a deletion of 
22q11.2 described, of which, six hundred-thirty eight (638) were male and six hundred-fifty 
seven (657) were female.  Once all data was extracted from the included studies, the prevalence 
of each trait per study, the overall prevalence of each trait across all studies, and the 95% 
confidence intervals were calculated (refer to figure 8 and table 9 in the Appendix).  Although 
not ideal, prevalence data was used in this study because generally the data provided in the 
articles were presented as such.  Predictor variables were classified as either class or continuous 
variables.  Class variables included ascertainment type, age range and continent and the 
remaining variables (maleness, number of years ago the study was published, and de novo 
deletion status) were classified as continuous.  Because the overall prevalence of these variables 
was provided and used to do the analysis, maleness and de novo deletion status were categorized 
as continuous variables 
 
Statistical analyses were conducted using SAS (statistical analysis system).  The general linear 
model was used to test the association between categorical and continuous predictor variables 
and outcome variables.  From the results, p values, R square values, R, and the number of 
observations (studies) used for each analysis, were obtained.  When the predictor variable was a 
continuous variable, the coefficient of the estimate was also be obtained.  From this regression 
analysis, we can test whether each predictor variable can significantly account for the differences 
in prevalence rates between studies.  Both weighted and unweighted analyses were performed 
and an alpha level of 0.05 was chosen as the threshold of significance.     
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 In order to perform a weighted analysis in SAS, a weight variable had to be created.  The weight 
variable was the total number of subjects in a particular study divided by the total number of 
subjects with the trait of interest.  In this manner, a different weight variable was created for each 
trait since not every study documented every trait.  This was then incorporated into the analysis 
using a “weight” command specific to SAS.   
 
In general, analyses were limited by the small number of studies and by the data presented within 
each study; thus limiting the ability to draw conclusions even when the finding was significant.  
Thus, it is important to consider the R squared value for this study due to it relative invariance to 
sample size.  For a summary of unweighted and weighted results, please refer to tables 1 through 
6 in the results section.   
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 4. RESULTS 
 
4.1. BY ASCERTAINMENT TYPE 
In order to determine the association between ascertainment mode and the prevalence of each 
trait, the ascertainment modes were categorized as discussed earlier.  The majority of study 
subjects fell into the mixed ascertainment category (MIX=4) with a total of one thousand-one 
hundred four (1,104) individuals from twelve studies.  The next largest category of ascertainment 
was “other” (OTH=5) with a total of one hundred eighty-three (183) individuals from eight 
studies.  In decreasing size order, next came those ascertained in medical or clinical genetics 
departments with one hundred sixty-two (162) subjects from four studies.  This was followed by 
those ascertained through craniofacial centers with one hundred three (103) subjects from four 
studies.  Lastly, thirty-six (36) subjects were recruited through a single VCFS center.    
 
Statistical analyses were carried out to determine whether each of the following traits was 
associated with the mode of ascertainment: ADHD, congenital heart defect (CHD), cleft palate 
(CP), hypotonia, palatal defects (includes CP, SMCP, VPI), the diagnosis of any psychiatric 
disorder, submucosal cleft palate (SMCP), schizophrenia, and velopharyngeal insufficiency 
(VPI).  Only the relationship between ascertainment type and ADHD was found to be 
statistically significant (p=0.02 unweighted and p=0.005 weighted; six observations, n=408).  
The R- squared value for this relationship, which shows the degree of association between two 
random variables, was found to be R2 = 0.99.  With regards to the remaining outcome variables, 
the p values range from 0.13 to 0.95 unweighted and 0.14 to 0.88 weighted.  R squared values 
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 range from 0.1 to 0.71 unweighted and 0.16 to 0.63 weighted (table 1).  Figure 2 depicts the 
overall prevalence of ADHD in those studies that evaluated individuals for this diagnosis.   
Table 1: Unweighted and weighted results by ascertainment type 
Data by Ascertainment Type 
     Unweighted analysis           Weighted analysis 
 
# of 
Studies 
# of 
Cases 
R 
squared R p value   
R 
squared R p value 
ADHD 6 408 0.99 0.99 0.02    0.99 0.99 0.005 
CHD  21 1,256 0.16 0.4 0.37   0.27 0.52 0.14 
CP 14 1,036 0.23 0.48 0.64   0.21 0.46 0.68 
Hypotonia 6 166 0.43 0.66 0.72   0.64 0.8 0.49 
Palatal 21 1,117 0.19 0.44 0.46   0.21 0.46 0.4 
Psychiatric d/o 9 288 0.65 0.81 0.13   0.58 0.76 0.19 
SMCP 10 901 0.71 0.84 0.13   0.63 0.8 0.21 
Schizophrenia 4 151 0.1 0.32 0.95   0.23 0.48 0.88 
VPI  13 946 0.33 0.57 0.28   0.16 0.4 0.64 
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Figure 5: Overall prevalence of ADHD by ascertainment type 
 P= 0.02 by unweighted analysis and p= 0.005 by weighted analysis; MIX, n=252; GEN, n=20; CC, n=25; OTH, 
n=111  
 
 
4.2. BY MALENESS 
Analyses were conducted to determine whether the prevalence of males is associated with the 
prevalence of a particular trait.  The outcomes that were evaluated include ADHD, CHD, CP, 
hypotonia, palatal defects, any psychiatric disorder, SMCP, schizophrenia, and VPI.  None of 
these relationships proved to be significant, p values range from 0.06 to 0.89 in the unweighted 
analysis and from 0.07 to 0.87 in the weighted analysis.  R squared values range from 0.003 to 
0.74 unweighted and 0.84 weighted.  Further investigation into the relationships between VPI 
and maleness as well as hypotonia and maleness may be warranted since the unweighted p 
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 values of each approach statistical significance (p=0.06); however, in the weighted analysis, both 
of these relationships moved away from statistical significance.  Refer to table 2 for results.   
Table 2: Unweighted and weighted results by maleness 
Data by Maleness 
     Unweighted analysis          Weighted analysis 
 
# of 
Studies 
# of 
Cases 
R 
squared R p value   
R 
squared R p value 
ADHD 5 383 0.43 0.66 0.23   0.71 0.84 0.07 
CHD  17 1,183 0.01 0.1 0.68   0.01 0.1 0.68 
CP 13 1,000 0.14 0.37 0.22   0.003 0.05 0.87 
Hypotonia 5 130 0.74 0.86 0.06   0.67 0.82 0.09 
Palatal 17 1,043 0.007 0.08 0.75   0.02 0.14 0.56 
Psychiatric d/o 8 263 0.08 0.28 0.51   0.20 0.45 0.26 
SMCP 9 865 0.003 0.05 0.89   0.09 0.3 0.42 
Schizophrenia 4 151 0.51 0.71 0.28   0.60 0.77 0.22 
VPI  12 931 0.31 0.56 0.06   0.04 0.2 0.53 
 
 
 
4.3. BY YEARS AGO 
Analyses were conducted to determine whether the number of years ago the study data was 
published could explain the differences in the reported prevalence of the traits of interest.  The 
traits that were included in this portion of the analysis again were ADHD, CHD, CP, hypotonia, 
palatal defects, any psychiatric disorder, SMCP, schizophrenia, and VPI.  An associated was 
detected between the numbers of years ago a study was published and the prevalence of cleft 
palate (p=<0.0001, unweighted; p=0.002 weighted) with an R squared value of 0.76 and 0.55 
(unweighted, weighted respectively).  The direction of the relationship is positive such that as the 
number of years ago increases, so does the prevalence of cleft palate (Figure 3).  In addition, the 
influence of the number of years ago a study was published on the prevalence of all palatal 
anomalies was also significant with a p value of 0.03 in both unweighted and weighted analyses 
(twenty one observations, n=1,117).  The R squared value here is 0.44.  Significance values for 
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 the other outcome variables range from 0.15 to 0.87 in the unweighted analysis and R squared 
values 0.007 to 0.42 (table 3).  Refer to figure 8 in the appendix to see the distribution of studies 
published by year.   
 
In addition to the relationships discussed, the weighted analysis revealed others that were 
significant as well.  In reference to ADHD, it was found that the number of years ago a study 
was published can explain 68% of the differences reported across studies by looking at the R 
squared value.  The p value is 0.04 and the direction of the relationship is negative.  This would 
be expected since as our knowledge of VCFS has increased over the years, there is more data 
that points to behavioral problems and thus it is being evaluated more frequently.  Finally, it was 
noted that the weighted analysis also revealed a significant association between this particular 
predictor and VPI (p=0.05, R squared = 0.3) with a negative direction of the relationship.  
Table 3: Unweighted and weighted results by number of years ago 
 
 
       Data by Years Ago 
     Unweighted analysis           Weighted analysis 
 
# of 
Studies 
# of 
Cases 
R 
squared R p value   
R 
squared R p value 
ADHD 6 408 0.37 0.61 0.20    0.68 0.82 0.04 
CHD  21 1,256 0.02 0.14 0.51    0.03 0.17 0.46 
CP 14 1,036 0.76 0.87 0.0001    0.55 0.74 0.002 
Hypotonia 6 166 0.007 0.08 0.87    0.009 0.09 0.86 
Palatal 21 1,117 0.23 0.48 0.03    0.23 0.48 0.03 
Psychiatric 
d/o 9 288 0.27 0.52 0.15    0.18 0.42 0.26 
SMCP 10 901 0.07 0.26 0.46    0.15 0.39 0.28 
Schizophrenia 4 151 0.42 0.65 0.35    0.53 0.73 0.28 
VPI  13 946 0.14 0.37 0.20    0.30 0.55 0.05 
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Figure 6: Overall prevalence of cleft palate by number of years ago 
Shows the overall prevalence of cleft palate based on number of years ago the study was published; 
p=<0.0001unweighted; p=0.002 weighted 
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Figure 7: Overall prevalence of palatal anomalies by the number of years ago  
Shows the overall prevalence of palatal anomalies based on the number of years ago the study was published; 
p=0.03 by unweighted and weighted analysis 
 
 
4.4. BY AGE RANGE 
Analyses were conducted to determine whether age influenced the prevalence of traits observed.  
Two studies did not specify the age range of the subjects used and therefore were eliminated 
from this portion of the analysis.  Again, traits examined included ADHD, CHD, CP, hypotonia, 
palatal defects, any psychiatric disorder, SMCP, schizophrenia, and VPI.  Of the relationships 
examined, a significant association was found between age range and CHD (p=0.0002 
unweighted and p=0.003 weighted; nineteen observations, n=1,230) as well as age range and 
schizophrenia (p=0.05 unweighted, p=0.03 weighted; four observations, n=151).  Please refer to 
table 4 for the complete results.   
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 Table 4: Unweighted and weighted results by age range 
Data by Age Range 
     Unweighted analysis          Weighted analysis 
 
# of 
Studies 
# of 
Cases 
R 
squared R p value   
R 
squared R p value 
ADHD 6 408 0.003 0.55 0.91    0.06 0.24 0.63 
CHD  19 1,230 0.66 0.81 0.0002    0.64 0.8 0.003 
CP 14 993 0.13 0.36 0.48    0.03 0.17 0.85 
Hypotonia 6 166 0.14 0.37 0.47    0.11 0.33 0.52 
Palatal 19 1,091 0.1 0.32 0.44    0.06 0.24 0.61 
Psychiatric 
d/o 9 288 0.38 0.62 0.24    0.49 0.7 0.13 
SMCP 10 901 0.03 0.17 0.64    0.31 0.56 0.09 
Schizophrenia 4 151 0.9 0.95 0.05    0.94 0.97 0.03 
VPI  12 946 0.09 0.3 0.66    0.17 0.41 0.44 
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Figure 8: Overall prevalence of CHD by age category 
p=0.0002 by unweighted analysis, p=0.03 by weighted analysis; Older (2 observations, n= 65) Mixed (13 
observations, n= 1,094) Younger (4 observations, n=71) 
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Figure 9: Overall prevalence of schizophrenia by age category 
p=0.05;  Mixed (3 observations, n=101), Older (1 observation, n=50) 
 
 
4.5. DE NOVO DELETION 
Analyses were conducted to determine whether the prevalence of de novo deletions is associated 
with the prevalence of the traits observed.   Traits examined included ADHD, CHD, CP, 
hypotonia, palatal defects, the diagnosis of any psychiatric disorder, SMCP, schizophrenia, and 
VPI.  Statistical significance was reached for the relationship between the prevalence of a 
submucosal cleft palate and prevalence of de novo deletions with p=0.02 in the unweighted 
analysis and p=0.01 weighted (three observations, n=580).  The R squared value for these results 
is 1.0 in both the weighted and unweighted analyses.  The analysis could not be carried out for 
ADHD, hypotonia and schizophrenia since not enough studies provided data on each of these 
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 traits in addition to deletion information.  The remaining analyses had p values ranging from 
0.08 to 0.85 and R squared values of 0.02 to 0.57 unweighted.  In the weighted analysis, 
significance was also reached for cleft palate (p=0.05) whereas it was not significant in the 
unweighted analysis   Refer to Table 5 below for the aforementioned results.  
Table 5: Unweighted and weighted results by deletion type 
 
Data by de novo Deletion Type 
     Unweighted analysis          Weighted analysis 
 
# of 
Studies 
# of 
Cases 
R 
squared R p value   
R 
squared R p value 
ADHD 2 272 * * *    * * * 
CHD  6 716 0.16 0.4 0.43    0.43 0.66 0.16 
CP 6 649 0.57 0.75 0.08    0.67 0.82 0.05 
Hypotonia 1 40 * * *    * * * 
Palatal 5 612 0.17 0.41 0.48    0.33 0.57 0.31 
Psychiatric 
d/o 3 96 0.47 0.68 0.52    0.67 0.82 0.39 
SMCP 3 580 1.0 1.0 0.02    1.0 1 0.01 
Schizophrenia 1 20 * * *    * * * 
VPI  4 600 0.02 0.14 0.85    0.12 0.65 0.66 
 
 
4.6. BY CONTINENT 
Geographical location can sometimes provide insight into variation in prevalence rates of 
phenotypic traits and therefore was chosen as a predictor variable.  All data collected for this 
research came from study populations in either Europe or North America.  Only two studies used 
samples that overlap both of these continents and therefore were not used in this portion of the 
analysis (Meinecke et al., 1986 and Kelly et al., 1993).  A total of seven hundred eighteen (718) 
subjects were described from the North American continent while eight hundred fifty-one (851) 
European individuals were described.  Significance was not observed in evaluation of any 
relationship between the traits of interest and the geographical location in the unweighted 
analysis (p values ranged from 0.09 to 0.73; R squared from 0.04 to 0.36).  The relationship 
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 between hypotonia and geographical location could not be tested because there were no 
European studies that reported data on hypotonia.  The weighted analysis did reveal significant 
association between palatal anomalies and the geographical location (p=0.02; R squared=0.28) 
(refer to Figure 7).  Table 6 summarizes this data.   
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Figure 10: Overall prevalence of palatal anomalies by geographic location 
Europe: overall prevalence = 44.8% (8 observations, n=638); N. America: overall prevalence = 66.1% (11 
observations , n=460) 
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 Table 6: Unweighted and weighted results by geographic location 
Data by Geographical Location 
     Unweighted analysis         Weighted analysis 
 
# of 
Studies 
# of 
Cases 
R 
squared R p value   
R 
squared R p value 
ADHD 6 408 0.12 0.35 0.51    0.31 0.56 0.25 
CHD  19 1,237 0.04 0.2 0.43    0.01 0.1 0.71 
CP 14 1,207 0.05 0.22 0.42    0.14 0.37 0.18 
Hypotonia 5 158 * * *    * * * 
Palatal 19 1,098 0.16 0.4 0.09    0.28 0.53 0.02 
Psychiatric 
d/o 9 268 0.1 0.32 0.42    0.10 0.32 0.4 
SMCP 9 893 0.24 0.49 0.18    0.35 0.59 0.1 
Schizophrenia 4 151 0.36 0.6 0.40    0.31 0.56 0.44 
VPI  12 938 0.01 0.1 0.73    0.03 0.17 0.57 
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 5. DISCUSSION 
This meta-analysis investigated explanations for the variation in reported prevalence data across 
studies for various manifestations commonly seen in individuals with Velocardiofacial 
syndrome.  Although the data is limited and many studies do not report on the same 
manifestations, thereby decreasing the sample sizes with which to analyze, the information 
remains useful.  Furthermore, other limiting factors include the uncertainty in sample overlap in 
the Ryan et al. (1997) study and the inability to obtain complete data due to barriers such as 
language and resource limitations.   
 
In addition to summarizing the published data, attempts were also made to not only explain the 
differences by identifying modifiers, but also to identify gaps in the current knowledge of this 
syndrome.   It is hoped that this information may provide insight into prospective research ideas.   
Mode of ascertainment or recruitment of study subjects can often create a bias in reporting; thus 
in this study the author intended to investigate the hypothesis that ascertainment mode would be 
significantly associated with the prevalence of various traits.  The ascertainment category MIX 
(4) has the greatest number of study subjects, thereby making it difficult to draw conclusions on 
individual modes of ascertainment.  Nevertheless, although the category MIX has a large sample 
size associated with it, it represents the lowest reported prevalence of ADHD.  This finding was 
further evaluated and it is noted that although only one study from this ascertainment category 
actually reported data on ADHD, though it was a large European study of five hundred fifty 
eight subjects (Ryan et al., 1997) of which two hundred fifty two (ages 3-18) were evaluated for 
behavioral and psychiatric problems.  Six individuals (2.38%) were diagnosed with ADHD, 
though the specific diagnostic criteria were not provided.  This figure is in stark contrast to other 
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 reports.  An earlier report by Papolos et al. (1996) reported a prevalence of ADHD of 36% and 
has since been corroborated by several other studies that cite a range of 35% to 46% (Arnold et 
al., 2001; Gothelf et al., 2004; Niklasson et al., 2001; and Feinstein et al., 2002).  This finding by 
Ryan et al. is interesting and should be further investigated as to why the great discrepancy in 
prevalence.   Explanations may include variability in the way in which the individual were 
diagnosed.  ADHD is difficult to diagnose in that some children’s behaviors vary with depending 
upon the setting they are in.  In addition, although mixed ascertainment may have been the 
largest category, a breakdown of the specific ascertainment sources may provide additional 
information though it is not commonly provided.  The association between other predictor 
variables and ADHD were assessed as well and only the predictor “number of years ago” in the 
weighted analysis was significant.  This would be expected since behavioral disorders were not 
known to be associated with this syndrome when it was initially being studied.  Of note is that it 
could not be determined whether or not ADHD could be associated with the origin of the 
deletion (de novo or familial) as only two studies reported both of these findings.  Those studies 
ascertaining through either craniofacial centers or medical/clinical genetics departments report 
data similar to other published rates of approximately 35% (Arnold et al., 2001; Papolos et al., 
1996).  The “other” category reports a somewhat higher overall prevalence of ADHD (43.2%) 
likely due to the fact that this category includes one study (n=51) that ascertained an unspecified 
portion of its subjects through a behavioral genetics clinic.  Further research is required to 
determine the true prevalence of ADHD in individuals with deletion 22q.   
 
Another hypothesis is that gender and age would have an influence on the presence or 
development of manifestations such as psychiatric illness.  Therefore, maleness and age range 
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 were evaluated separately to see if they are associated with the prevalence rates of 
behavioral/psychiatric illness.  The current study did not find any significant association between 
the prevalence of males and any of the behavioral dependent variables tested such as ADHD, 
psychiatric illness or schizophrenia.   This is in contrast to what is found in the literature on 
studies of ADHD in the general population.  In these articles, it is commonly suggested that 
ADHD has a higher prevalence rate in males than females (Biederman and Faraone, 2004).  
There are several possibilities why this might be.  One explanation is that because young girls 
often present with less hyperactivity (i.e. primarily the inattentive form) than boys therefore, it is 
possible that the parents may be less likely to seek intervention services.  Therefore, it is possible 
that boys may be diagnosed earlier or more frequently thus explaining the gender differences 
reported by some.  Secondly, it may be that because those reports on individuals in the general 
population are more likely to be on an unbiased group of subjects, it would be less likely that the 
subjects have the same underlying cause for their lack of attention control.  In children with 
VCFS, it has been shown that the type of attentional problems in these children is non-verbal, 
which differs from children with ADHD in the general population.  The underlying cause in 
VCFS is possibly related to COMT gene activity and the dysregulation of dopamine.  Because 
there is a common underlying defect (the deletion) in both genders in this syndrome, it may then 
affect them the same way such that we would not see a gender difference.  However, small 
sample size limits our ability to draw a conclusion that there is no association between maleness 
and the prevalence of ADHD because the current meta-analysis only includes six articles that 
evaluated the prevalence of ADHD in the VCFS population.   
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 In terms of schizophrenia and the prevalence of any psychiatric disorder, again there was not a 
significant association with the prevalence of males and these outcomes.  This however, may not 
be as surprising for similar reasons as those discussed for ADHD.  In the literature, based on 
schizophrenia in the general population, there is not a gender difference in terms of the lifetime 
incidence only in the age of onset.   
 
Age range was found to have a significant influence on the prevalence of schizophrenia 
(p=0.0498).  As discussed earlier, age categories m, o, and y (mixed, older = ≥15y, younger = 
<15y) were based on data suggesting an earlier age of onset of behavior problems and/or 
psychiatric disorders in the VCFS population.  In the general population there is a distinct 
difference in age of onset of schizophrenia in particular between the genders that is often 
considered a hallmark of the illness.  Although this difference exists and has been documented in 
almost all cultures where the illness has been studied, the onset typically occurs during the 
reproductive years in both sexes (adolescence to menopause).  It has been hypothesized that the 
protective anti-dopaminergic properties of estrogen may influence the onset of schizophrenia 
because although men and women have a comparable lifetime risk of schizophrenia, women tend 
to have a later onset (Hafner, 2003; Halbreich and Kahn, 2003).   The average age of onset in 
men, as characterized by the first psychotic episode, is in their early twenties and in women 
occurs in the late twenties.  In the VCFS population however, though debatable, there are some 
studies that suggest that the age of onset is earlier (Usiskin et al., 1999). 
 
It would be interesting to learn if this pattern of discrepant onset age between the sexes holds 
true in the VCFS population.  In addition, it would be valuable to learn whether or not the gender 
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 differences in onset age are related to differing vulnerabilities of each sex and again whether or 
not that would hold true in those with VCFS since they would likely have the same underlying 
cause for their schizophrenia.   
 
Although significance was reached in the current research between age range and schizophrenia, 
only four observations were considered in the analysis as only four studies reported data on both 
schizophrenia and age range.  Furthermore, only data in the “mixed” and “older” categories was 
available with very small total sample sizes (n=101 and n=50 respectively; see figure 6).  This 
limits our ability to draw conclusions based on this data.  In this case however, the R squared 
value is important to consider.  The R squared value is 0.9 and 0.94 in the unweighted and 
weighted analyses respectively meaning that 90-94% of the differences in the prevalence of 
schizophrenia between studies can be attributed to the age range.  This is not a surprising finding 
however since we would expect the prevalence of schizophrenia to increase as age increases.  
This is exactly what is shown in Figure 6; the “older” population has a greater prevalence than 
the “mixed” population.  Moreover, an important factor to address regarding mental illness is the 
issue of cognitive impairment in individuals with VCFS as the prevalence of psychiatric illness is 
assumed to be higher in those with LD in the general population (without VCFS), though good 
estimates are not available.  Studies report that learning disabilities or cognitive impairment is 
nearly universal in those with VCFS (Driscoll et al., 1992; Shprintzen, 2000).   
 
In a study by Feinstein et al. (2002) that examined twenty-eight individuals with VCFS and 
twenty-nine age and cognitively matched controls found that although both groups had high rates 
of psychiatric disorders and behavioral problems, there was no significant difference between the 
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 two groups.  The question remains, are the rates of psychosis different between those with VCFS 
and those without VCFS with comparable cognitive impairment?   
 
Another interesting finding in regards to maleness as a predictor, is the trend that was noted with 
palatal anomalies.  Although none of the relationships were found to be significantly associated, 
all four outcomes (CP, SMCP, VPI, and all palatal anomalies) have a negative relationship with 
the predictor variable.  This indicates that as the prevalence of males increases, the prevalence of 
these palatal findings decrease implying that these findings could potentially be more common in 
female subjects with VCFS.   
 
Palatal anomalies were analyzed several ways.  As mentioned earlier, they were first broken 
down into individual findings, cleft palate, submucosal cleft palate, and velopharyngeal 
insufficiency, and then analyzed together as a whole.  Cleft palate prevalence was found to be 
significantly associated with the number of years ago the study was published (p= < 0.0001) with 
an R-squared value of 0.76 and a positive estimate of the coefficient.  This finding implies that 
cleft palate prevalence was reported to be higher in the past than what it is currently.  This 
finding is striking because one would not expect the reported prevalence of cleft palate to change 
over time since this is one of the clinical findings that is typically detectable at birth or very early 
in childhood depending upon the extent of the cleft.  Additionally, there has been little evidence 
to suggest that the incidence of cleft palate has changed over the last twenty-thirty years.  One 
explanation may be that the two articles that were published the greatest number of years ago 
(refer to Figure 3) were both published by Shprintzen et al. (1978, 1981) who first described the 
syndrome.  He makes note in his first article that cleft palate is one of the unifying features in 
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 this first cohort of patients (though not all subjects had a cleft palate); thus ascertainment or 
reporting bias may have played a role as this may have been a feature in children that were more 
likely to bring them to attention and therefore be evaluated for such a syndrome.  The 
aforementioned articles published by Shprintzen et al. report prevalence rates of cleft palate of 
41.6% and 28.2% (1978 and 1981 respectively), which are the highest of the data used for this 
meta-analysis.  The remaining twelve articles cite prevalence data that ranges from 5.5% to 
16.1% in the last eleven years.   Lastly, it is possible that the reported decreased prevalence of 
cleft palate in more recent years may represent decreased fitness for various reasons.  In those 
individuals ascertained for cleft palate may have a more severe palatal defect which may also 
mean that they have a more severe phenotype in general including greater cognitive impairment.  
There also has been evidence that some individuals with a cleft palate may have issues of self-
esteem and therefore may be less likely to reproduce.  It is also possible that individuals who are 
aware of their risks to pass on the deletion to the next generation may choose not to reproduce.   
 
Similarly, when evaluating the influence of the number of years ago on the combination of all 
palatal anomalies, it too was found to be significant in both the weighted and unweighted 
analysis (p=0.03).  The R-squared value is 0.23 with a positive estimate of the coefficient 
indicating that as the number of years ago increased, so did the number of palatal anomalies 
therefore; the prevalence data being reported today is lower than that which was reported in the 
past.  The overall prevalence of all palatal anomalies was 54.1% (range of 16.7% to 100%) from 
twenty-one observations (total n=1,117).   
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 It is well established that the majority of all patients carrying a deletion at 22q11.2 have a 
sporadic or de novo deletion.  There has been a lot of research conducted in this area in attempt 
to define any phenotypic differences there may be between these individuals and those with a 
familial deletion.  There has been little evidence for specific differences between these groups.  
In the current research, a significant association was identified between the predictor variable “de 
novo deletion” and the presence of a SMCP (p=0.01, three observations, n=580) with a positive 
estimate of the coefficient; however due to limited data, the true significance of this result is 
uncertain.  Here again, the R squared value may be more relevant and was found to be very high 
(R2= 0.999), thus stating that 99-100% of the variation of the prevalence of SMCP between 
studies can be accounted for by the prevalence of a de novo deletion.  The prevalence range 
reported in the three studies was 5% to 16.7% with an overall prevalence of 6.6% (mean 
prevalence of 10.01%).  The largest study, which evaluated four hundred ninety-six subjects 
found the lowest prevalent rate.   
 
Similarly, a significant association was identified between prevalence of a de novo deletion and 
the prevalence of cleft palate (p=0.5, 6 observations/studies); again due to a small number of 
studies included, it is valuable to look at R squared (0.57 unweighted and 0.67 weighted).  More 
than half of the differences between studies can be accounted for by the prevalence of a de novo 
deletion (positive relationship).   
 
Analyses looking for factors that may suggest an association with the prevalence of CHD were 
conducted; only age range had a significant association with this finding (p=0.0002 unweighted, 
p= 0.003 weighted).  This finding is interesting because by looking at Figure 5, one can see that 
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 the highest overall prevalence (77.5%) was in the “younger” category (<15 years of age) and this 
category also has a very small n value (n=71).   The “older” age category (≥ 15 years) has the 
lowest overall prevalence (33.8%, n=65).  The largest age category (“mixed”, n=1,094) has an 
overall prevalence similar to that of the younger group, 75.9%.  Because the sample sizes here 
are very different, it is difficult to draw any conclusions, but it can be hypothesized that some of 
these differences are real.  For example, we could argue that the younger category would be 
more likely than the older group to have a heart defect since it is more likely that older 
individuals may have died if they had one.  The mixed category is more difficult to explain in 
that it includes individuals ranging in age from birth to fifty-two years of age.  It is possible that 
there are individuals in this category with less severe defects and therefore improved survival 
rates as CHD is the primary cause of early mortality in VCFS.   
 
One study (Cohen et al., 1999) compared the clinical phenotype in adults and children by 
reviewing case reports on one hundred twenty-six adults and comparing their findings with a 
study by Ryan et al. (1997) which evaluated five hundred fifty-eight subjects, the majority of 
which were under the age of eighteen years (89%).  They found that adults with deletion 22q11.2 
had fewer heart defects which supports the proposed explanation.  Other studies that examined 
affected parent-child pairings have reported similar results in which the transmitting parent is 
less likely to have a heart defect (Ryan et al., 1997; Leana-Cox et al., 1996). 
 
In the unweighted analysis, the geographical location (Europe versus North America) was not 
found to be significantly associated with any of the outcome variables.  However, with the 
weighted analysis, the relationship with combined palatal anomalies became significant 
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 (p=0.02).  Please refer back to Figure 7 for a graphical depiction.  A possible explanation for this 
result may be that there is ascertainment bias in the two samples.  All of the Europe studies 
reporting on palatal anomalies ascertained their subjects through either “mixed” ascertainment or 
by those that fall into the “other” category.  In the studies conducted in North America, the 
ascertainment modes are a combination of all possibilities therefore; it is possible that the 
increase in palatal findings as a whole may be due to this.   
 
As was alluded to earlier, in studies that are underpowered such as many of the analyses above, it 
is sometimes better to not emphasize p values but to focus on an value that is not so dependent 
upon the size of the sample.  In this case, we could focus more on the R squared values that were 
calculated.  By choosing an arbitrary cutoff of 50%, we would see that there are many more 
outcomes which seem to have an association with predictor variables.   
 
Ascertainment type would seem to be associated with ADHD, psychiatric disorders, hypotonia 
and SMCP as all of the R squared values here are ≥ 0.50 in either the weighted or unweighted 
analysis.   Continuing with this, we could also note that maleness accounts for greater than 50% 
of the differences between studies for ADHD, hypotonia, and schizophrenia.  This is interesting 
because as is noted in the general population, there are gender differences in the occurrence or 
diagnosis of ADHD.  In this study, the p value was not found to be significant and the direction 
of the relationship here is positive saying that as the prevalence of males increase, so does the 
prevalence of ADHD.  In contrast, in the general population, we do not see a gender difference in 
the prevalence of schizophrenia, but here we see that there is a negative direction of the 
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 relationship between maleness and schizophrenia.  This difference may be accounted for by the 
possible differences in age of onset which have not been fully delineated.   
 
The number of years ago a study was published would also appear to be associated with an 
outcome that was not considered to be significant by the p value (p=0.28).  The number of years 
ago accounts for greater than 50% of the differences in the reported prevalence of schizophrenia 
in the weighted analysis. Interestingly, the relationship is positive suggesting that as the number 
of years ago increases, so does the prevalence of schizophrenia.  Since behavioral and psychiatric 
disorders were not known to be a part of the syndrome originally, this finding is unexpected.  
Perhaps the first estimates were high due in part to VCFS and in part to chance, which prompted 
more research on larger samples revealing a prevalence that was somewhat lower than what was 
originally thought.  Other relationships with a possible association by the R squared value are 
with number of years ago and ADHD and cleft palate (R squared = 0.76 and 0.55 unweighed and 
weighted analysis) though both of these were also significant by p value.   
 
Again, considering R squared values alone, there appears to be an association between age range 
and CHD as well as age range and schizophrenia using the arbitrary cutoff of 50%.  The R 
squared value for age range and CHD is 0.64 and 0.66 (unweighted, weighted respectively) and 
for age range and schizophrenia, R squared = 0.9 and 0.94 (unweighted, weighted respectively).  
Again, with schizophrenia, the association with age range would be an expected finding since as 
an at-risk person gets older, their likelihood to be diagnosed would increase.  In both 
relationships, these associations are also significant by p value.  
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 In regards to the prevalence of de novo deletions, the analyses demonstrated that this predictor 
accounts for greater than 50% of the between study differences in the prevalence of cleft palate, 
SMCP and any psychiatric disorder.  The relationships between de novo deletions and cleft 
palate and SMCP were also found to be significant by p value, however the R squared value 
supports this further since the number of studies (observations) was small for both.  In fact, the R 
squared value was 0.999 or 1.0 for SMCP and de novo deletions stating that nearly 100% of the 
differences in SMCP prevalences between studies can be attributed to the prevalence of de novo 
deletions.  In terms of the between study differences in the prevalence of any psychiatric 
disorder, 67% (in the weighted analysis) can be accounted for by the increase in prevalence of de 
novo deletions though this was not a significant relationship by p value.  Again, a small sample 
number of observations were used in this analysis therefore, the true meaning is difficult to 
determine.  Finally, there were no R squared values found to be greater than 0.5 in the analyses 
using continent as the predictor variable.  It is interesting that the prevalence of palatal anomalies 
was found to be associated with this predictor variable by p value (p=0.02) with a moderately 
sized number of observations, yet the R squared value using the arbitrary cutoff of 0.5 does not 
support that there is a strong association.  The R value would be 0.53 and by most accounts this 
would however be considered a moderate association.  This demonstrates that depending upon 
how one interprets the data, can come to differing conclusions.   
 
 
 
 
 
57 
 6. CONCLUSIONS 
The purpose of this study was to seek explanations for the differences in the reported prevalence 
rates of the various findings examined here; to more accurately estimate the prevalence of each 
of the nine traits examined; to provide insight into future research; and to improve the ability for 
genetic counselors and clinicians to provide more appropriate services and offer appropriate 
resources.   
 
Differences in prevalence rates between studies in the literature were found to be as large as a 
93% difference for psychiatric disorders and VPI and 83% for palatal findings.  This meta-
analysis was conducted in an attempt to explain some of these discrepancies by analyzing how 
several predictor variables may be associated with the prevalence of different outcomes.  The 
predictor variables chosen were 1) ascertainment mode 2) maleness (prevalence of males) 3) 
number of years ago each study was published 4) age range 5) prevalence of de novo deletions 
and 5) continent or geographical location.  The nine traits of which the prevalence was evaluated 
for were: ADHD, congenital heart defects, cleft palate, submucosal cleft palate, velopharyngeal 
insufficiency, palatal anomalies in combination, any psychiatric disorder, schizophrenia, and 
history of hypotonia.  Overall prevalence rates are as follows: ADHD 17.2%, CHD 73.5%, cleft 
palate 11.6%, submucosal cleft palate 17.0%, velopharyngeal insufficiency 35.1%, any palatal 
anomaly 54.1%, any psychiatric disorder 34.4%, schizophrenia 12.6%, and hypotonia 64.5%.   
 
Mode of ascertainment was found to be associated with the prevalence of ADHD, although the 
analysis included only six observations.  Ascertainment was not significantly associated with any 
other findings.  Surprisingly, maleness was not associated by p value with the prevalence of any 
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 of the traits examined however it nears significance for the prevalence of ADHD and VPI.  The 
number of years ago a study was published was associated with the reported differences in 
prevalence between studies with regards to ADHD, cleft palate, palatal anomalies, and VPI.  Age 
range was significantly associated with the differences between studies on congenital heart 
defects and schizophrenia.  The prevalence of de novo deletions was significantly associated with 
the prevalence of cleft palate and a submucosal cleft palate.  Lastly, geographical location was 
associated with the prevalence of palatal anomalies, with North America reporting higher 
prevalence rates than Europe though with a smaller sample size.   
 
Because so many of the current analyses used a small number of observations, it is difficult to 
draw conclusions.  However, using R squared values and being aware of which analyses have the 
smaller sample sizes, it is possible to provide insight in future research opportunities.  Future 
studies using much larger sample sizes of individuals with VCFS, especially in regards to 
ADHD, schizophrenia and psychiatric disorders in general will be extremely beneficial.  The 
prevalence of these findings was much higher than that in the general population.  Studies 
regarding the etiology of these behavioral findings in the general population too, will be 
beneficial to that population and likely to the VCFS population as well.  Dopamine regulation 
has long been hypothesized to play a role in schizophrenia, and there is now evidence that the 
COMT gene commonly deleted in individuals with VCFS, also functions to regulate dopamine 
activity.  Moreover, further research into the age of onset of the behavioral and psychiatric 
disorders will be important especially if we find that the onset is earlier in the VCFS population 
as a fewer number of years would be available for early intervention services and preventive 
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 treatment if and when it becomes available.  Psychiatric and behavioral problems are a 
significant public health burden as most psychiatric illnesses are lifelong, debilitating diseases.   
 
An area where the above analyses could be improved is to conduct analyses involving multiple 
variables simultaneously.  For instance, it would be interesting to evaluate both ascertainment as 
well as age range when looking for explanations in the reported prevalence differences for 
psychiatric disorders.  Again due to the limitations in sample sizes and number of observations, 
this would be difficult to do until more data is available.   
 
At this time, it is still difficult to provide patients and families accurate prognoses.  Palatal 
findings are certainly significant in this illness as approximately 54% were found to have some 
type of such anomaly.  VPI is difficult to diagnose in very early life and may not present a 
problem until the child begins to speak or has delayed speech.  If this speech delay is not 
addressed immediately, the child will lose valuable time that he/she could have been receiving 
targeted speech therapy.   If we know that a child has VPI or is susceptible to it having a 
diagnosis of VCFS, speech therapy could potentially start around that time that speech should 
normally begin rather than waiting for the delay to occur.  There is evidence as well that 
hypotonia is an underlying factor in VPI, thus children with VCFS with hypotonia, without a 
cleft, may be at a higher risk to have VPI and therefore speech problems.   
 
Although not discussed in the current study, learning disabilities and cognitive impairment is 
significant in this population.  More specifically, children with VCFS tend to demonstrate a 
different type of learning difficulty compared to those with LD in the general population.  
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 Children with VCFS tend to have a non-verbal learning disorder such that their verbal IQ is 
greater than their performance IQ.  Non-verbal learning disability affects motor skills, social 
skills, and executive functioning skills (involving attention).  Knowing that these difficulties are 
likely to present themselves during childhood would make obtaining intervention services as 
early as possible beneficial to their future success.   
 
Services that should be offered or provided for these families as mentioned already include early 
intervention for motor skills associated with hypotonia, speech therapy for speech delays due to 
VPI and/or cleft palate and cognitive interventions for learning disabilities.  A great place for 
parents or family members to look for support is an organization called Velo-Cardio-Facial 
Syndrome Educational Foundation.  This group offers listings for various areas of the United 
States and also abroad and is meant to educate and provide support to those dealing with 
someone with this syndrome.  There is also a quarterly publication available through the 
Children’s Hospital of Philadelphia called “22q and you”, a newsletter for patients, families and 
professionals as well.  These and additional resources are listed below.   
 
To locate a genetic counselor: 
National Society of Genetic Counselors 
www.nsgc.org/resourcelink.asp
 
Chromosome Deletion Outreach, Inc 
P.O. Box 724 
Boca Raton, FL  33429 
561-395-4252 
www.chromodisorder.org
 
Genetic Professional Societies (provides a listing of societies and contact information) 
www.kumc.edu/gec/prof/soclist.html
 
Velo-Cardio-Facial Syndrome Educational Foundation 
(http://www.vcfsef.org/SupportGroups/index.htm
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The Children’s Hospital of Philadelphia 
The Clinical Genetics Center 
One Children’s Center 
34th and Civic Center Boulevard 
Philadelphia, PA  19104 
215-590-2920 
lunny@email.chop.edu 
 
National Institutes of Health 
National Library of Medicine 
8600 Rockville Pike 
Bethesda, MD  20894 
www.nlm.nih.gov
 
 
62 
 APPENDIX   
 
 
[   P – 1.96 √P (1-P)   ]   to   [  P + 1.96 √P (1-P)   ]  
                N                                          N                                             
        
Figure 11: Calculation for 95 percent confidence interval of a proportion 
P= proportion, N= total number of subjects/observations 
 
 
 
Table 7: Table of p values 
 
 ADHD CHD CP Hypotonia Palatal Psych SMCP Schizo VPI 
Ascertain type 0.0158 0.37 0.6358 0.716 0.4566 0.1306 0.1277 0.9465 0.2829 
Male 0.2258 0.6812 0.2151 0.0611 0.7494 0.5105 0.8885 0.2847 0.058 
Years ago 0.1977 5058 <0.0001 0.8682 0.0287 0.1485 0.4587 0.3513 0.2014 
Age range 0.9147 0.0002 0.4789 0.4724 0.4378 0.2423 0.6434 0.0498 0.6557 
de novo * 0.4339 0.0848 * 0.4838 0.5181 0.0168 * 0.8498 
Continent 0.5092 0.4285 0.4199 * 0.0853 0.4161 0.1788 0.4006 0.7257 
* indicates no data available 
 
 
 Table 8: Direction of the relationship between predictor and outcome variables 
              Unweighted Analysis                     Weighted Analysis 
  Male  
Years 
Ago 
De 
novo   Male  Years Ago 
De 
novo 
ADHD positive negative *   positive negative * 
CHD  positive positive negative   negative positive negative
Cleft palate negative positive positive   positive positive positive 
Hypotonia negative positive *   negative positive * 
Palatal negative positive positive   positive positive positive 
Psychiatric 
D/O negative positive positive   negative positive positive 
SMCP negative positive positive   positive positive positive 
Schizophrenia negative positive *   negative positive * 
VPI  negative positive positive   negative positive positive 
* indicates no data available 
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 Table 9: Overall prevalence ranges, prevalence data, and confidence intervals 
 
Outcome Prevalence range 
Mean 
Prevalence 95% ci 
Overall 
Prevalence 95% ci 
ADHD 2.38 - 46.4 34.12 17.16,  51.08 17.2 13.5,  20.8 
CHD  6.7 - 84.6 66.33 58.20,  74.45 73.5 71.0,  75.9 
 
Cleft palate 5.6 - 41.7 14.56 9.04,  20.08 11.6 9.6,  13.5 
Hypotonia 25 - 100 60.83 29.55,  92.10 64.5 57.2,  71.7 
Palatal 16.67 - 100 59.9 46.72,  73.08 54.1 51.2,  57.0 
Psychiatric 
D/O 3.3 - 96.0 40.71 17.68,  63.74 34.4 28.9,  39.9 
SMCP 5.04 - 84.62 39.31 15.27,  63.35 17 14.5,  19.4 
Schizophrenia 3.3 - 24 11.29 -2.89,  25.48 12.6 7.3,  17.9 
VPI  6.67 - 100 43.42 25.28,  61.56 35.1 32.1,  38.1 
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Figure 12: Number of publications by year  
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Table 10: Overall prevalence and sample size by ascertainment type 
 
 Overall prevalence, (# of observations), (n) 
      
 Craniofacial 
Centers =1 
VCFS  
Clinic = 2 
Medical/Clinical Genetics 
Clinics = 3 
Mixed Ascertainment = 
4 
Other or 
unspecified = 5 
ADHD 36, (1), (25) * 35, (1), (20) 2.38, (1), (252) 43.2, (3), (111) 
CHD  69.2, (3), (78) * 65.7, (2),(102) 76.2, (12), (994) 53.7, (5), (82) 
Cleft palate 19.6, (3), (56) 5.56, (1), (36) 14.3, (2), (84) 11.0, (5), (776) 11.9, (3), (84) 
Hypotonia  46.5, (2), (43) 100, (1), (36) 50, (1), (40) 70.0, (2),(47) * 
Palatal anomalies 66.1, (3),(56) 97.2, (1), (36) 63.1, (2), (84) 51.0, (10), (869) 55.6, (5),(72) 
Psychiatric D/O  96.0, (1), (25) * 60, (1), (20) 23.4, (3), (141) 29.4, (4),(102) 
SMCP  72.0, (2), (25) 92.0, (1), (36) 15.5, (2), (84) 11.6, (4), (724) 15.6, (1), (32) 
Schizophrenia * * 10, (1), (20) 16.3, (2), (80) 7.8, (1), (51) 
VPI  57.1, (3), (56) * 38.9, (1), (72) 33.0, (6), (784) 34.2, (3), (34) 
*indicates no data available 
 
Table 11: Overall prevalence data and sample size by age category 
 
                Overall prevalence, (# of observations), (n) 
   Mixed (m)    Older (o)           Younger (y) 
ADHD 15.9, (5), (383) * 36, (1), (25)
CHD  75.9, (13), (1,094) 33.8, (2), (65) 77.5, (4), (71)
Cleft palate 11.8, (10), (930)  13.33, (1), (15) 8.8, (3), (91)
Hypotonia  57.0, (4), (90) * 74.0, (2), (76)
Palatal anomalies 54.6, (12), (919) 35.4, (2), (65) 50.5, (5), (107)
Psychiatric D/O  24.7, (5), (194) 38.5, (2), (65) 89.7, (2),  (29)
SMCP  14.0, (8), (853) * 70.8, (2), (48)
Schizophrenia 6.9, (3), (101) 24.0, (1),  (50) *
VPI  36.0, (9),  (869) 66.67, (1), (15) 17.0, (2), (47)
* indicates no data available 
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Table 12: Overall prevalence data and sample size by geographic location 
 Overall prevalence, (# of observations), (n) 
 North America  Europe  
ADHD   39.7, (3), (73) 12.2, (3), (335) 
CHD  72.3, (10), (510) 74.6, (9),  (727) 
Cleft palate 14.0 (9), (439) 9.9, (5), (597) 
Hypotonia  66.5, (5), (158) * 
Palatal anomalies 66.1, (11),  (460) 44.8, (8), (638) 
Psychiatric D/O 49.3, (3), (75) 29.1, (6), (213) 
SMCP  33.2, (7), (365) 5.7, (2), (528) 
Schizophrenia 6.0, (2), (50) 15.8, (2), (101) 
VPI  38.2, (8), (406) 33.0, (4), (532) 
* indicates no data available 
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 Table 13: Summary of study data  
Study Year N 
 
Ascertain continent age M:F Familial FamilialP Denovo DenovoP 
Arnold  2001 20 
 
3 NA m 9:11 3.00 0.05 17.00 0.05 
Botto 2003 43 4 NA y 21:22         
Digilio 2003 15 5 EU o 5:10 15.00 0.21 72.00 0.21 
Driscoll 1992 15 5 NA             
Du Montcel 1996 12 4 EU y           
Eliez 2000 4 5 EU y 2:2         
Feinstein 2002 28 5 NA m 18:10         
Ford 2000 35 1 NA m 18:17         
Gerdes 1999 40 3 NA y 19:21 5.00 0.10 35.00 0.10 
GothelfB 2004 51 5 EU m 33:18         
GothelfC 2003 40 4 EU m 28:12         
Havkin 2000 36 2 NA y           
Hopkin 2000 12 3 NA y 5:7 6.00 0.03 6.00 0.03 
Kelly 1993 11 4               
Kerstjens 1999 90 3 NA m 45:45 7.00 0.19 69.00 0.19 
KitsiouTzeli 2004 17 4 EU m 14:3 3.00 0.04 14.00 0.04 
LeanaCox 1996 12 5 NA m 3:9         
McDonald- 
McGinnA 1999 250 
4 
NA m 120:130         
McDonald- 
McGinnB 2001 30 
4 
NA m 14:16         
Meinecke 1986 8 4   m 6:2         
Murphy 1999 50 4 EU o 15:35         
Niklasson 2001 32 5 EU m 13:19         
Oskarsdottir 2004 35 4 EU m           
Papolos 1996 25 1 NA y           
Ravnan 1996 31 1 NA m 15:16         
Ryan 1997 558 4 EU m 197:202 79.00 0.29 37.00 0.29 
ShprintzenA 1978 12 1 NA m 4:8         
ShprintzenB 1981 39 4 NA m 15:24         
Swillen 1997 37 5 EU m 19:18 12.00 0.09 25.00 0.09 
P= prevalence 
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 Table 14: Summary of study data by palatal anomalies 
 
 
Study CP CP N SMCP SMCP N VPI VPI N Palatal Palatal N 
ShprintzenB 11.00 39.00 28.00 39.00 26.00 39.00 39.00 39.00 
Arnold                  
Botto 5.00 43.00     6.00 43.00 11.00 43.00 
Digilio 2.00 15.00     10.00 15.00 10.00 15.00 
Driscoll         1.00 15.00 15.00 15.00 
Du Montcel             4.00 12.00 
Eliez         2.00 4.00 2.00 4.00 
Feinstein                 
Ford 1.00 13.00 11.00 13.00 12.00 13.00 12.00 13.00 
Gerdes                 
GothelfB                 
GothelfC             10.00 12.00 
Havkin 2.00 36.00 33.00 36.00     35.00 36.00 
Hopkin 1.00 12.00 1.00 12.00     2.00 12.00 
Kelly             10.00 11.00 
Kerstjens 11.00 72.00 12.00 72.00 28.00 72.00 51.00 72.00 
KitsiouTzeli 2.00 17.00     2.00 17.00 4.00 17.00 
LeanaCox             3.00 6.00 
McDonald-
McGinnA 20.00 181.00 29.00 181.00 62.00 181.00 111.00 181.00 
McDonald-
McGinnB                 
Meinecke     2.00 8.00 2.00 8.00 4.00 8.00 
Murphy             13.00 50.00 
Niklasson 5.00 32.00 5.00 32.00     10.00 32.00 
Oskarsdottir                 
Papolos                 
Ravnan 5.00 31.00     8.00 31.00 13.00 31.00 
Ryan 47.00 496.00 25.00 496.00 161.00 496.00 233.00 496.00 
ShprintzenA 5.00 12.00 7.00 12.00 12.00 12.00 12.00 12.00 
Swillen 3.00 37.00             
CP=cleft palate 
SMCP=submucosal cleft palate 
VPI=velopharyngeal insufficiency 
N=number of subjects examined 
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 Table 15: Summary of study data by behavioral traits 
 
Study Schizo Schizo N Psych Psych N ADHD ADHD N 
ShprintzenB             
Arnold  2.00 20.00 12.00 20.00 7.00 20.00 
Botto             
Digilio     4.00 15.00     
Driscoll             
Du Montcel             
Eliez     2.00 4.00     
Feinstein         13.00 28.00 
Ford             
Gerdes             
GothelfB 4.00 51.00 4.00 51.00 21.00 51.00 
GothelfC             
Havkin             
Hopkin             
Kelly             
Kerstjens             
KitsiouTzeli             
LeanaCox             
McDonaldMcGinnA             
McDonaldMcGinnB 1.00 30.00 1.00 30.00     
Meinecke             
Murphy 12.00 50.00 21.00 50.00     
Niklasson     20.00 32.00 14.00 32.00 
Oskarsdottir             
Papolos     24.00 25.00 9.00 25.00 
Ravnan             
Ryan     11.00 61.00 6.00 252.00 
ShprintzenA             
Swillen             
Schizo=schizophrenia 
Psych=any psychiatric disorder 
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 Table 16: Summary of study data – other traits 
 
Study CHD  CHD N Hypotonia Hypotonia N 
ShprintzenB 33.00 39.00 29.00 39.00 
Arnold          
Botto 35.00 43.00     
Digilio 1.00 15.00     
Driscoll 8.00 15.00     
Du Montcel 10.00 12.00     
Eliez 3.00 4.00     
Feinstein         
Ford 27.00 35.00     
Gerdes     20.00 40.00 
GothelfB         
GothelfC 8.00 12.00     
Havkin     36.00 36.00 
Hopkin 7.00 12.00     
Kelly 8.00 11.00     
Kerstjens 60.00 90.00     
KitsiouTzeli 12.00 17.00     
LeanaCox 8.00 11.00     
McDonald-McGinnA 164.00 222.00     
McDonald-McGinnB         
Meinecke 4.00 8.00 2.00 8.00 
Murphy 21.00 50.00     
Niklasson         
Oskarsdottir 28.00 35.00     
Papolos         
Ravnan 18.00 31.00 10.00 31.00 
Ryan 435.00 545.00     
ShprintzenA 9.00 12.00 10.00 12.00 
Swillen 24.00 37.00     
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